Trial Profile
Phase 1/2 Study Of Ixazomib In Combination With Cyclophosphamide And Dexamethasone In Patients With Newly Diagnosed Immunoglobulin Light Chain AL Amyloidosis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 30 Sep 2022
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Ixazomib (Primary)
- Indications Amyloid light-chain amyloidosis
- Focus Adverse reactions
- 28 Sep 2022 Status changed from recruiting to completed.
- 24 Aug 2020 Planned End Date changed from 1 Jun 2020 to 1 Jun 2021.
- 24 Aug 2020 Planned primary completion date changed from 1 Jun 2020 to 1 Jun 2021.